Progression of lesions of the arterial wall evaluated by ultrasonic biopsy in asymptomatic subjects and in diabetic and hyperlipidemic patients treated with bezafibrate. A 4-year follow-up

Non-invasive arterial ultrasonic biopsy (UB) has been used to evaluate and follow-up arterial wall changes in four years in asymptomatic subjects, hyperlipidemics and diabetics. Both groups of patients were randomised in a treatment group (bezafibrate 400 mg daily) and in a control group. The rate o...

Full description

Saved in:
Bibliographic Details
Published inMinerva cardioangiologica Vol. 40; no. 1-2; p. 15
Main Authors Cesarone, M R, Laurora, G, De Sanctis, M T, Pomante, P, Belcaro, G
Format Journal Article
LanguageItalian
Published Italy 01.01.1992
Subjects
Adult
Aged
Arteries - diagnostic imaging
Arteries - pathology
Bezafibrate - administration & dosage
Bezafibrate - therapeutic use
Biopsy
Cholesterol - blood
Diabetes Mellitus - blood
Diabetes Mellitus - drug therapy
Diabetes Mellitus - pathology
Female
Humans
Hyperlipidemias - blood
Hyperlipidemias - drug therapy
Hyperlipidemias - pathology
Male
Middle Aged
Time Factors
Triglycerides - blood
Ultrasonography
Online AccessGet more information

Cover

More Information
Summary:Non-invasive arterial ultrasonic biopsy (UB) has been used to evaluate and follow-up arterial wall changes in four years in asymptomatic subjects, hyperlipidemics and diabetics. Both groups of patients were randomised in a treatment group (bezafibrate 400 mg daily) and in a control group. The rate of progression (ROP) into the next higher UB class was recorded by UB scans repeated every six months. In diabetics and hyperlipidemics the rate of progression (ROP, namely the percent of patients progressing to the next class) was significantly higher than the ROP in the asymptomatic subjects. However in the bezafibrate group the ROP was significantly lower than that observed in the controls. As each UB class corresponds to different levels of risks of occult coronary ischemia and cardiovascular events in the following four years, the reduction of ROP with bezafibrate was an important and positive achievement.
ISSN:0026-4725